Overview

Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Docetaxel may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving daily doses of docetaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel in treating patients with refractory or recurrent advanced gynecologic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Docetaxel